Szelog Jason T, Shah Neil S, Camejo M David
Department of Ophthalmology, University of Missouri-Kansas City, Kansas City, MO, USA.
Tufts Medical Center, New England Eye Center, Retina Department, Boston, MA, USA.
J Vitreoretin Dis. 2022 Nov 18;7(1):83-86. doi: 10.1177/24741264221136907. eCollection 2023 Jan-Feb.
To describe a patient initially diagnosed with age-related macular degeneration (AMD) who was ultimately determined to have progressing pentosan polysulfate sodium (PPS)-associated maculopathy leading to secondary cystoid macular edema (CME) 10 years after cessation of PPS.
An interventional case report is presented.
A 57-year-old woman diagnosed with AMD presented with unilateral worsening vision and metamorphopsia from CME. A detailed history showed a 3-year course of PPS, which had been discontinued 10 years previously. This led to the diagnosis of PPS-associated maculopathy. After topical NSAID and corticosteroid treatment failed, intravitreal bevacizumab resolved the symptoms. CME developed in the fellow eye 5 months later and also responded to bevacizumab.
This case emphasizes the importance of a thorough review of past medication and medical histories in patients with pigmentary retinopathy and supports the use of antivascular endothelial growth factor therapy as an option to treat CME secondary to PPS-associated maculopathy.
描述一名最初被诊断为年龄相关性黄斑变性（AMD）的患者，最终确定其在停止使用戊聚糖多硫酸钠（PPS）10年后出现进行性PPS相关性黄斑病变，导致继发性黄斑囊样水肿（CME）。
呈现一份介入性病例报告。
一名被诊断为AMD的57岁女性因CME出现单侧视力恶化和视物变形。详细病史显示其有3年PPS用药史，已于10年前停药。这导致诊断为PPS相关性黄斑病变。局部使用非甾体抗炎药和皮质类固醇治疗无效后，玻璃体内注射贝伐单抗缓解了症状。5个月后，对侧眼出现CME，对贝伐单抗也有反应。
该病例强调了对色素性视网膜病变患者全面回顾既往用药和病史的重要性，并支持使用抗血管内皮生长因子疗法作为治疗PPS相关性黄斑病变继发CME的一种选择。
